TO discuss the unusual features of topiramate-induced acute angle closure glaucoma, its pathophysiologic mechanisms, and treatment controversies, and to report the first anterior segment optical coherence tomography (OCT) of this condition.
Methods
Literature review and case report with OCT findings.
Results
Topiramate-induced angle closure is usually bilateral and associated with acute myopia; the ocular pressure is often not very highly elevated. Ciliochoroidal detachment with ciliary body anterior rotation is typically present and was demonstrated easily in our case with anterior segment OCT. Pilo-carpine exacerbates this condition and peripheral iridotomy is not indicated, nor is iridoplasty Treatment consists of replacing topiramate with appropriate medication, strong cycloplegia, and topical steroids.
Conclusions
It is important to recognize this form of acute secondary angle closure in order to treat it properly, avoiding harmful medication and unnecessary surgery.
LeungD.Y., LeungH., BaigN.Topiramate and asymptomatic ocular angle narrowing: a prospective pilot study. Eye2009; 23: 2079–81.
5.
ThambiL., KapcalaL.P., ChambersW.Topiramate-associated secondary angle-closure glaucoma: a case series. Arch Ophthalmol2002; 120: 1108.
6.
PalomaresP., AnselemL., Diaz-LlopisM.Optical coherence tomography for diagnosis and monitoring of angle-closure glaucoma induced by topiramate. Can J Ophthalmol2007; 42: 633–4.
7.
CraigJ.E., OngT.J., LouisD.L., WellsJ.M.Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. Am J Ophthalmol2004; 137: 193–5.
MedeirosF.A., ZhangX.Y., BerndA.S., WeinrebR.N.Angle closure glaucoma associated with ciliary body detachment in patients using topiramate. Arch Ophthalmol2003; 121: 282–5.
15.
SankarP.S., PasqualeL.R., GrosskreutzC.L.Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol2001; 119: 1210–1.
LowS., NolanW.Anterior segment imaging for glaucoma: where are we and what next. Clin Experiment Ophthalmol2009; 37: 431–3.
18.
ShankR.P., GardockiJ.F., StreeterA.J.An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia2000; 41(Suppl): S3–9.
19.
Viet TranH., RavinetE., SchnyderC.Blood-brain barrier disruption associated with topiramate-induced angle-closure glaucoma of acute onset. Klin Monatsbl Augenheilkd2006; 223: 425–7.
20.
SchiavinoD., NuceraE., BuonomoA.A case of type IV hypersensitivity to topiramate and carbamazepine. Contact Dermat2005; 52: 161–2.
21.
KriegP.H., SchipperI.Drug-induced ciliary body oedema: a new theory. Eye1996; 10: 121–6.
22.
QuigleyH.A., FriedmanD.S., CongdonN.G.Possible mechanisms of primary angle-closure and malignant glaucoma. J Glaucoma2003; 12: 167–80.
23.
QuigleyH.A.What's the choroid got to do with angle closure?Arch Ophthalmol2009; 127: 693–4.
24.
RheeD.J., GoldbergM.J., ParrishR.K.Bilateral angle closure glaucoma and ciliary body swelling from Topiramate. Arch Ophthalmol2001; 119: 1721–3.
25.
De SimoneG., ScozzafavaA., SupuranC.T.Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates?Chem Biol Drug Des2009; 74: 317–21.
